News coverage about Coherus Biosciences (NASDAQ:CHRS) has trended somewhat positive on Tuesday, according to Accern. The research firm identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Coherus Biosciences earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 48.096953657747 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
- Coherus BioSciences, Inc. (CHRS) moves 15.20% higher to SMA-50 – The Stocks News (press release) (thestocksnews.com)
- Coherus BioSciences, Inc. (CHRS) to touch earnings growth of -47.50% for this year – Wallstreet Investorplace (wallstreetinvestorplace.com)
- Coherus BioSciences, Inc. (NASDAQ:CHRS) – Investor’s Roundup (P/E Analysis) – Nasdaq Journal (nasdaqjournal.com)
- Coherus BioSciences, Inc. (CHRS) receives consensus rating of 3.00 – Nasdaq Fortune (press release) (nasdaqfortune.com)
- May This Data Fuel Up Investor’s Confidence – Coherus BioSciences Inc (NASDAQ: CHRS) – Alpha Beta Stock (alphabetastock.com)
Shares of Coherus Biosciences (NASDAQ:CHRS) traded up $0.25 during mid-day trading on Tuesday, hitting $12.35. The company had a trading volume of 264,958 shares, compared to its average volume of 801,227. The company has a current ratio of 5.12, a quick ratio of 5.12 and a debt-to-equity ratio of 3.33. Coherus Biosciences has a twelve month low of $8.05 and a twelve month high of $24.70. The company has a market cap of $751.77, a P/E ratio of -2.66 and a beta of 3.62.
Several research firms have recently weighed in on CHRS. ValuEngine downgraded shares of Coherus Biosciences from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Citigroup increased their target price on shares of Coherus Biosciences from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, March 9th. BidaskClub lowered shares of Coherus Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, February 3rd. Zacks Investment Research upgraded Coherus Biosciences from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a report on Wednesday, January 3rd. Finally, Maxim Group restated a “buy” rating and issued a $15.00 price objective (down previously from $20.00) on shares of Coherus Biosciences in a research note on Friday, March 9th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $29.33.
COPYRIGHT VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Coherus Biosciences (CHRS) Share Price” was first reported by BBNS and is owned by of BBNS. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://baseballnewssource.com/2018/03/20/coherus-biosciences-chrs-receives-media-sentiment-rating-of-0-21/2023393.html.
About Coherus Biosciences
Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.